Biotech Values

[Mufaso]

Obesity along with Type 2 Diabetes is a major cause NASH. If these new drugs reduce obesity/better control Type 2 Diabetes , it follows that fewer people will develop NASH and the addressable market could be significantly smaller than previously thought.

These new obesity drugs are having a negative effect on the prospects of all of the companies with NASH compounds. MDGL/AKRO/ENTB /VKTX are all down significantly as a result. (VKTX is getting hit not only on NASH but on competitiveness concerns with their obesity drug).

MDGL which is the most advanced is down approx. 15% today at the time of this post.